Precision BioSciences, Inc. (DTIL) News
Filter DTIL News Items
DTIL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DTIL News Highlights
- DTIL's 30 day story count now stands at 4.
- Over the past 26 days, the trend for DTIL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about DTIL are GENE, VIVO and HUGE.
Latest DTIL News From Around the Web
Below are the latest news stories about PRECISION BIOSCIENCES INC that investors may wish to consider to help them evaluate DTIL as an investment opportunity.
Trade Alert: The Chief Financial Officer Of Precision BioSciences, Inc. (NASDAQ:DTIL), John Kelly, Has Just Spent US$60k Buying 38% More SharesWhilst it may not be a huge deal, we thought it was good to see that the Precision BioSciences, Inc. ( NASDAQ:DTIL... |
Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine SummitDURHAM, N.C., September 22, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022. |
Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment ConferenceDURHAM, N.C., September 07, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. |
Precision BioSciences Announces Senior Leadership Organizational ChangesDURHAM, N.C., September 02, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team reporting to Michael Amoroso, Chief Executive Officer (CEO). |
Analysts Offer Insights on Healthcare Companies: Albireo Pharma (ALBO), Precision BioSciences (DTIL) and Ayala Pharmaceuticals (AYLA)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma (ALBO – Research Report), Precision BioSciences (DTIL – Research Report) and Ayala Pharmaceuticals (AYLA – Research Report) with bullish sentiments. Albireo Pharma (ALBO) In a report released today, Andreas Argyrides from Wedbush maintained a Buy rating on Albireo Pharma, with a price target of $61.00. The company's shares closed last Monday at $24.93. According to TipRanks.com, Argyrides is a 3-star analyst with an average return of -6.7% and a 42.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals. |
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Oramed Pharmaceuticals (ORMP)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Precision BioSciences (DTIL – Research Report) and Oramed Pharmaceuticals (ORMP – Research Report) with bullish sentiments. Precision BioSciences (DTIL) In a report issued on August 11, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on Precision BioSciences, with a price target of $9.00. The company's shares closed last Friday at $2.01, close to its 52-week low of $1.11. According to TipRanks. |
Investors in Precision BioSciences (NASDAQ:DTIL) from a year ago are still down 80%, even after 16% gain this past weekOver the last month the Precision BioSciences, Inc. ( NASDAQ:DTIL ) has been much stronger than before, rebounding by... |
Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in FocusKodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases. |
BMO Capital Sticks to Their Buy Rating for Precision BioSciences (DTIL)In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Precision BioSciences (DTIL - Research Report), with a price target of $7.00. The company's shares closed yesterday at $1.61.Biliouris covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Crispr Therapeutics AG, and Precision BioSciences. According to TipRanks, Biliouris has an average return of 37.8% and an 88.89% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Precision BioSciences with a $10.80 average price target, which is a 570.81% upside from current levels. |
Analysts Conflicted on These Healthcare Names: Aeglea Biotherapeutics (AGLE), SI-Bone (SIBN) and Precision BioSciences (DTIL)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aeglea Biotherapeutics (AGLE – Research Report), SI-Bone (SIBN – Research Report) and Precision BioSciences (DTIL – Research Report). Aeglea Biotherapeutics (AGLE) Wells Fargo analyst Yanan Zhu maintained a Hold rating on Aeglea Biotherapeutics today and set a price target of $1.50. The company's shares closed last Tuesday at $0.42, close to its 52-week low of $0.37. According to TipRanks.com, Zhu is ranked #6477 out of 8001 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aeglea Biotherapeutics with a $3.25 average price target, a 673. |